MGMT and neoplasm: The NRG BN007 phase 2/3 trial evaluated the combination of nivolumab and ipilimumab using the better-tolerated dosing regimen explored in CHECKMATE 143 and allowing the use of tumor-treating fields at the treating physicians’ discretion in newly diagnosed MGMT promoter unmethylated GBM.